Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis

Dahlia M. Besmer, Jennifer M. Curry, Lopamudra D. Roy, Teresa L. Tinder, Mahnaz Sahraei, Jorge Schettini, Sun Il Hwang, Yong Y. Lee, Sandra J Gendler, Pinku Mukherjee

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

MUC1 is overexpressed and aberrantly glycosylated in more than 60% of pancreatic ductal adenocarcinomas. The functional role of MUC1 in pancreatic cancer has yet to be fully elucidated due to a dearth of appropriate models. In this study, we have generated mouse models that spontaneously develop pancreatic ductal adenocarcinoma (KC), which are either Muc1-null (KCKO) or express human MUC1 (KCM). We show that KCKO mice have significantly slower tumor progression and rates of secondary metastasis, compared with both KC and KCM. Cell lines derived from KCKO tumors have significantly less tumorigenic capacity compared with cells from KCM tumors. Therefore, mice with KCKO tumors had a significant survival benefit compared with mice with KCM tumors. In vitro, KCKO cells have reduced proliferation and invasion and failed to respond to epidermal growth factor, platelet-derived growth factor, or matrix metalloproteinase 9. Further, significantly less KCKO cells entered the G 2-M phase of the cell cycle compared with the KCM cells. Proteomics and Western blotting analysis revealed a complete loss of cdc-25c expression, phosphorylation of mitogen-activated protein kinase (MAPK), as well as a significant decrease in nestin and tubulin-α2 chain expression in KCKO cells. Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling. This is the first study to utilize a Muc1-null PDA mouse to fully elucidate the oncogenic role of MUC1, both in vivo and in vitro.

Original languageEnglish (US)
Pages (from-to)4432-4442
Number of pages11
JournalCancer Research
Volume71
Issue number13
DOIs
StatePublished - Jul 1 2011

Fingerprint

Mucin-1
Adenocarcinoma
Neoplasm Metastasis
Growth
Neoplasms
Mitogen-Activated Protein Kinases
Nestin
Gastrin-Secreting Cells
Platelet-Derived Growth Factor
Matrix Metalloproteinase 9
Tubulin
Pancreatic Neoplasms
Epidermal Growth Factor
Cell Division
Proteomics
Cell Cycle
Western Blotting
Phosphorylation
Cell Proliferation
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Besmer, D. M., Curry, J. M., Roy, L. D., Tinder, T. L., Sahraei, M., Schettini, J., ... Mukherjee, P. (2011). Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Research, 71(13), 4432-4442. https://doi.org/10.1158/0008-5472.CAN-10-4439

Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. / Besmer, Dahlia M.; Curry, Jennifer M.; Roy, Lopamudra D.; Tinder, Teresa L.; Sahraei, Mahnaz; Schettini, Jorge; Hwang, Sun Il; Lee, Yong Y.; Gendler, Sandra J; Mukherjee, Pinku.

In: Cancer Research, Vol. 71, No. 13, 01.07.2011, p. 4432-4442.

Research output: Contribution to journalArticle

Besmer, DM, Curry, JM, Roy, LD, Tinder, TL, Sahraei, M, Schettini, J, Hwang, SI, Lee, YY, Gendler, SJ & Mukherjee, P 2011, 'Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis', Cancer Research, vol. 71, no. 13, pp. 4432-4442. https://doi.org/10.1158/0008-5472.CAN-10-4439
Besmer, Dahlia M. ; Curry, Jennifer M. ; Roy, Lopamudra D. ; Tinder, Teresa L. ; Sahraei, Mahnaz ; Schettini, Jorge ; Hwang, Sun Il ; Lee, Yong Y. ; Gendler, Sandra J ; Mukherjee, Pinku. / Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. In: Cancer Research. 2011 ; Vol. 71, No. 13. pp. 4432-4442.
@article{3d8bcb0a98ff4c5fb7d6e92b4660436c,
title = "Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis",
abstract = "MUC1 is overexpressed and aberrantly glycosylated in more than 60{\%} of pancreatic ductal adenocarcinomas. The functional role of MUC1 in pancreatic cancer has yet to be fully elucidated due to a dearth of appropriate models. In this study, we have generated mouse models that spontaneously develop pancreatic ductal adenocarcinoma (KC), which are either Muc1-null (KCKO) or express human MUC1 (KCM). We show that KCKO mice have significantly slower tumor progression and rates of secondary metastasis, compared with both KC and KCM. Cell lines derived from KCKO tumors have significantly less tumorigenic capacity compared with cells from KCM tumors. Therefore, mice with KCKO tumors had a significant survival benefit compared with mice with KCM tumors. In vitro, KCKO cells have reduced proliferation and invasion and failed to respond to epidermal growth factor, platelet-derived growth factor, or matrix metalloproteinase 9. Further, significantly less KCKO cells entered the G 2-M phase of the cell cycle compared with the KCM cells. Proteomics and Western blotting analysis revealed a complete loss of cdc-25c expression, phosphorylation of mitogen-activated protein kinase (MAPK), as well as a significant decrease in nestin and tubulin-α2 chain expression in KCKO cells. Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling. This is the first study to utilize a Muc1-null PDA mouse to fully elucidate the oncogenic role of MUC1, both in vivo and in vitro.",
author = "Besmer, {Dahlia M.} and Curry, {Jennifer M.} and Roy, {Lopamudra D.} and Tinder, {Teresa L.} and Mahnaz Sahraei and Jorge Schettini and Hwang, {Sun Il} and Lee, {Yong Y.} and Gendler, {Sandra J} and Pinku Mukherjee",
year = "2011",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-10-4439",
language = "English (US)",
volume = "71",
pages = "4432--4442",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis

AU - Besmer, Dahlia M.

AU - Curry, Jennifer M.

AU - Roy, Lopamudra D.

AU - Tinder, Teresa L.

AU - Sahraei, Mahnaz

AU - Schettini, Jorge

AU - Hwang, Sun Il

AU - Lee, Yong Y.

AU - Gendler, Sandra J

AU - Mukherjee, Pinku

PY - 2011/7/1

Y1 - 2011/7/1

N2 - MUC1 is overexpressed and aberrantly glycosylated in more than 60% of pancreatic ductal adenocarcinomas. The functional role of MUC1 in pancreatic cancer has yet to be fully elucidated due to a dearth of appropriate models. In this study, we have generated mouse models that spontaneously develop pancreatic ductal adenocarcinoma (KC), which are either Muc1-null (KCKO) or express human MUC1 (KCM). We show that KCKO mice have significantly slower tumor progression and rates of secondary metastasis, compared with both KC and KCM. Cell lines derived from KCKO tumors have significantly less tumorigenic capacity compared with cells from KCM tumors. Therefore, mice with KCKO tumors had a significant survival benefit compared with mice with KCM tumors. In vitro, KCKO cells have reduced proliferation and invasion and failed to respond to epidermal growth factor, platelet-derived growth factor, or matrix metalloproteinase 9. Further, significantly less KCKO cells entered the G 2-M phase of the cell cycle compared with the KCM cells. Proteomics and Western blotting analysis revealed a complete loss of cdc-25c expression, phosphorylation of mitogen-activated protein kinase (MAPK), as well as a significant decrease in nestin and tubulin-α2 chain expression in KCKO cells. Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling. This is the first study to utilize a Muc1-null PDA mouse to fully elucidate the oncogenic role of MUC1, both in vivo and in vitro.

AB - MUC1 is overexpressed and aberrantly glycosylated in more than 60% of pancreatic ductal adenocarcinomas. The functional role of MUC1 in pancreatic cancer has yet to be fully elucidated due to a dearth of appropriate models. In this study, we have generated mouse models that spontaneously develop pancreatic ductal adenocarcinoma (KC), which are either Muc1-null (KCKO) or express human MUC1 (KCM). We show that KCKO mice have significantly slower tumor progression and rates of secondary metastasis, compared with both KC and KCM. Cell lines derived from KCKO tumors have significantly less tumorigenic capacity compared with cells from KCM tumors. Therefore, mice with KCKO tumors had a significant survival benefit compared with mice with KCM tumors. In vitro, KCKO cells have reduced proliferation and invasion and failed to respond to epidermal growth factor, platelet-derived growth factor, or matrix metalloproteinase 9. Further, significantly less KCKO cells entered the G 2-M phase of the cell cycle compared with the KCM cells. Proteomics and Western blotting analysis revealed a complete loss of cdc-25c expression, phosphorylation of mitogen-activated protein kinase (MAPK), as well as a significant decrease in nestin and tubulin-α2 chain expression in KCKO cells. Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling. This is the first study to utilize a Muc1-null PDA mouse to fully elucidate the oncogenic role of MUC1, both in vivo and in vitro.

UR - http://www.scopus.com/inward/record.url?scp=79959891751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959891751&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-4439

DO - 10.1158/0008-5472.CAN-10-4439

M3 - Article

C2 - 21558393

AN - SCOPUS:79959891751

VL - 71

SP - 4432

EP - 4442

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -